Delhi Pharmaceutical Sciences and Research University (DPSRU) has developed COROQUIL-Zn-- an Ayurveda drug which effectively reduces viral load in Covid patients.
“The results of clinical studies showed that COROQUIL-Zn treatment produces a significant reduction in viral load (46%, 89%, and 100% patients becoming RT-PCR negative on 5th, 7th and 14th day of treatment as compared to 6%, 44%, and 89%, respectively in the standard of care group) with a distinct clinical improvement in the severity of dyspnea and recovery rate,” DPSRU said in a press statement.
Speaking to DTMT, Prof Ramesh K Goyal, Vice Chancellor, DPSRU, said that the drug will also be effective in the delta variant of Covid.
“The drug also helps in management of post Covid complications,” he added.
He said that the drug is yet to get the final approval of Indian Ministry of Ayush for its availability in market. The formulation, which has been developed in association with Remedium Therapeutics Pvt Ltd, Chennai, has been granted the license for manufacturing and sales by Jammi Pharmaceuticals Pvt Ltd, Chennai.
Clinical trials of phase three study for capsules got completed at Sri Lakshmi Super Specialty Hospital, Bengaluru in mild- and moderate –Covid patients as per the Ayush and ICMR guidelines for Pandemic Trials and Ethics Committee standards and approval with Clinical Trials Registry – India (CTRI) registration.
Prof Ramesh K Goyal pointed out that COROQUIL-Zn is the first formulation in the world that modulates ACE-2 receptors of SARS-Cov-2. It can prevent and treat the Covid patients and can also prevent post-Covid complications.
“It disrupts the viral spike protein-host cell ACE2 receptor interaction and reduces the virus entry into human host cells. In the cell-based studies carried out in Calu-3 human lung cell lines under the guidance of Dr Kamlendra Singh (Univeristy of Missouri, USA), COROQUIL-Zn produced a dose-dependent decrease in the viral load by reducing the function of ACE-2 receptors,” said Prof Goyal.
These findings were consistent with the results of molecular docking studies at DPSRU.
“Since the ACE-2 is the key target for SARS-Covid- virus, COROQUIL-Zn has two effects. It reduces the entry and replication of virus and it modulates the Renin Angiotensin system that is responsible for cytokine surge (immune disturbances) leading to respiratory, heart, neurological, renal, and gastrointestinal and eye complications, we are hopeful that the concept and the medicine will find its place internationally,” said Dr Goyal.
According to DPSRU, COROQUIL-Zn is a novel repurposed Ayurveda formulation for treating patients with Covid using edible plant ingredients and Zinc oxide documented Ayurveda Pharmacopoeia.
The clinical trial study was an open-label, two-arm, parallel design, prospective, single-centre, phase 3 study in 120 patients to assess the safety and efficacy of COROQUIL-Zn when compared to the standard of care treatment.